Home Elmiron Lawsuits

Elmiron Lawsuits

Elmiron lawsuits claim people suffered serious vision damage after taking the drug. As of June 2024, there were 1,750 lawsuits pending in a federal MDL. There has been no formal Elmiron recall, but some Elmiron lawsuits have confidentially settled in 2023. Drugwatch's legal partners are currently not accepting new Elmiron lawsuit cases.

Last Modified: June 3, 2024
Fact Checked
Legally Reviewed

Drugwatch.com content is legally reviewed for accuracy and quality.

Examples of trusted legal reviewers include qualified mass torts lawyers and certified paralegals.

Drugwatch.com writers gather lawsuit information by studying court records, watching lawsuit proceedings and speaking with experienced attorneys.

Why Trust DrugWatch?

Drugwatch.com has been empowering patients for more than a decade

Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008. We’ve also connected thousands of people injured by drugs and medical devices with top-ranked national law firms to take action against negligent corporations.

Our team includes experienced medical writers, award-winning journalists, researchers and certified medical and legal experts. Drugwatch.com is HONCode (Health On the Net Foundation) certified. This means the high-quality information we provide comes from credible sources, such as peer-reviewed medical journals and expert interviews.

The information on Drugwatch.com has been medically and legally reviewed by more than 30 expert contributors, including doctors, pharmacists, lawyers, patient advocates and other health care professionals. Our writers are members of professional associations, including American Medical Writers Association, American Bar Association, The Alliance of Professional Health Advocates and International Society for Medical Publication Professionals.

About Drugwatch.com

  • Assisting patients and their families since 2008.
  • Helped more than 12,000 people find legal help.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed medical and legal information site.
Learn More About Us


"Drugwatch opened my eyes to the realities of big pharmacy. Having a family member with major depression and anxiety, I was looking for information on her medications. I found information that was very helpful, that her psychiatrist never told her."
Marianne Zahren Patient’s Family Member
  • Google Business Rating
  • BBB A+ Rating Logo

Latest Elmiron Lawsuit Updates

As of June 2024, there are 1,750 Elmiron cases pending in multidistrict litigation in the U.S. District Court of New Jersey before Judge Brian R. Martinotti. A total of 1,982 lawsuits have been filed in the MDL. Settlements are expected in MDL 2973.

Status of Elmiron Lawsuits
  • May 2024:
    Cases continued to settle confidentially, and MDL numbers slowly decrease as the litigation winds down. Judge Martinotti cancelled a settlement conference that was supposed to be held May 13 and hasn't rescheduled it yet.
  • November 2023:
    Lawyers were still accepting new cases. Some cases have been settled confidentially.
  • March 2023:
    The first bellwether trial had been scheduled to start at the end of the month. Some lawyers thought that trials were paused as Elmiron manufacturer Janssen Pharmaceuticals negotiates settlements.
  • October 2022:
    Judge Martinotti rescheduled the first bellwether trial, Maria Windham v. Janssen Pharmaceuticals, Inc., et al., 20-cv-14670, to March 27, 2023. There hadn't been a ruling on the other bellwethers, but these dates were likely moved down to accommodate the rescheduling of the first trial.
  • September 2022:
    The judge scheduled the first bellwether trial in the Elmiron MDL for January 2023. A second trial was scheduled to begin in March 2023 and a third was to follow in May 2023.
  • July 2022:
    Judge Brian Martinotti approved 14 plaintiffs' attorneys for the Plaintiffs' Steering Committee, a group of attorneys who oversee and coordinate the litigation for the plaintiffs in the MDL.
Show More

Researchers published the first studies linking Elmiron to pigmentary maculopathy in 2018. In 2020, Janssen updated the drug label to include a warning for “changes in the retina of the eye (pigmentary maculopathy).” In 2020, shortly after adding the warning to the label, plaintiffs filed the first Elmiron lawsuits.

The first bellwether trial in the Elmiron multidistrict litigation in New Jersey, Windham v. Janssen Pharmaceuticals, Inc., et al. 2:20-cv-14670, was scheduled for January 2023 and was later moved to March 27, 2023. In April 2023, the parties jointly agreed to withdraw all motions, presumably for settlement talks.

“Elmiron litigation is a few years old at this point. This is a unique case because typically these MDLs move extremely slowly. But we had gotten a lot of the legwork done before the MDL was assigned. The first trial in that case was supposed to happen back in March 2023, and it got postponed,” mass torts and product liability attorney Trent B. Miracle told Drugwatch.

Why Do Elmiron Lawsuits Claim?

Elmiron lawsuits were filed against Janssen Pharmaceuticals by plaintiffs who suffered vision problems that could lead to blindness, including maculopathy.

Plaintiffs claim Elmiron, a medication used to treat interstitial cystitis, caused their vision damage and that it is a dangerously defective drug. According to lawsuits, Janssen withheld adverse event reports from the public, medical community and the U.S. Food and Drug Administration.

The lawsuits call for Janssen to pay compensation for permanent vision injuries.

Trent Miracle
“[Patient’s] lives have been profoundly changed by this. They were taking something they thought was just going to help their day-to-day quality of life because they were in pain. And now, they can’t do things that they took for granted — like just sitting down and reading a book — because they've got maculopathy. The middle of their field of vision could be gone.”
Trent B. Miracle mass torts and product liability attorney

Elmiron Patients File Suit

People began filing lawsuits against Janssen in 2020. Samantha Padelford filed one of the more recent lawsuits in 2023. Padelford took Elmiron from 2001 to 2008, and she claimed she nor her physician were warned about the risks of vision damage. She now suffered from “substantially impaired vision, among other symptoms.”

Three of the earlier lawsuits belonged to Jeanette Milburn, Valarie Hull and Kimberly Pelczar. The three women claimed long-term Elmiron use caused them to develop loss of night vision, pigmentary maculopathy, vision degradation, retinal injury and retinal hemorrhage. They claimed Elmiron was defective and that Janssen failed to warn them and their doctors of the risk of permanent vision damage.

Elmiron Lawsuit Settlement Amounts

In 2023, Janssen and Johnson & Johnson started quietly settling some Elmiron lawsuits, although they have not publicly disclosed any official settlement amounts. Some lawyers estimate that Elmiron lawsuit settlement amounts could reach hundreds of thousands of dollars.

Because there have been no trials, jury verdicts or global Elmiron settlement offers, determining the potential Elmiron lawsuit settlement amounts is challenging. Bellwether trial verdicts usually serve as a benchmark for the value of these cases.

Courts scheduled the first Elmiron bellwether trial for March 2023 but later canceled and never rescheduled it as attorneys continue to work on a potential global settlement.

Lawyer Trent B. Miracle explains the qualifications for an Elmiron lawsuit, including a maculopathy diagnosis.

Elmiron Linked to Maculopathy

Several studies have linked Elmiron, the brand name of pentosan polysulfate sodium (PPS), to a unique type of maculopathy that only occurs in Elmiron users called pigmentary maculopathy. This type of maculopathy could lead to blindness and there is no cure.

“In 2018, eye physicians published the first report of retinal damage associated with Elmiron use,” Miracle told Drugwatch. “Since then, the medical literature regarding eye damage and vision loss associated with Elmiron continues to grow.”

Anatomy of an Eye
Elmiron may damage a part of the retina called the macula, causing vision problems.

“[Patient’s] lives have been profoundly changed by this. They were taking something they thought was just going to help their day-to-day quality of life because they were in pain. And now, they can’t do things that they took for granted — like just sitting down and reading a book — because they’ve got maculopathy. The middle of their field of vision could be gone,” Miracle said.

Will There Be an Elmiron Recall?

There has not been an Elmiron recall, despite studies linking the long-term use of the interstitial cystitis drug to potentially permanent vision damage.

The drug has been on the market since 1996 and is still the only oral treatment available for the condition. Janssen didn’t warn about the risk of retinal pigmentary maculopathy until June 2020.

The FDA published the new label with the maculopathy warning but has not issued a statement or safety communication about it. So far, the Agency hasn’t asked Janssen to recall the drug and the drugmaker hasn’t said it plans to issue a recall.

Please seek the advice of a medical professional before making health care decisions.